본문 바로가기
KERD
논문KCI 등재

새로운 COX-2 억제제

New COX-2 Inhibitors

성윤경|김담
대한내과학회 (The Korean Association Of Internal Medicine)|2016.12|대한내과학회지 (The Korean Journal of Medicine)|제91권 제3호|pp. 250-256|DOI http://dx.doi.org/10.3904/kjm.2016.91.3.250

1

조회

0

다운로드

5

인용

0

참고문헌

키워드

Safety안전성Anti-inflammatory agentsNon-steroidal비스테로이드 소염제사이클로옥시제나제 저해제Cyclooxygenase inhibitors
주제분류내과학

초록

COX-2 억제제는 뛰어난 염증 억제 및 진통 효과와 함께위장관계 부작용과 출혈 경향은 낮은 비교적 안전한 약제로현재 다양한 상황에 널리 이용되고 있다. 그러나 이미 몇몇의 COX-2 억제제는 심혈관계 부작용으로 인하여 시장에서철수되었고, 나머지의 COX-2 억제제 또한 장기적인 안전성에 있어 자유롭지 못하다.

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation. There are two kinds of NSAID classified according to the selectivity of COX-2 inhibition: non-selective NSAIDs and cyclooxygenase (COX)-2 inhibitors. Non-selective NSAIDs have a high incidence of gastrointestinal and bleeding-associated adverse events, while COX-2 inhibitors are safer in terms of these events. However, COX-2 inhibitors are thought to cause increased cardiovascular events. The COX-2 inhibitors rofecoxib and valdecoxib were withdrawn from the market over safety concerns. Three COX-2 inhibitors are now available in South Korea after the recent approval of etoricoxib and polmacoxib for osteoarthritis patients. After reviewing the history of and recent studies about the safety of COX-2 inhibitors, physicians should find new uses for old drugs.

참고문헌 (33)

  1. Abramson S, "The mechanisms of action of nonsteroidal antiinflammatory drugs", Clin Exp Rheumatol, 7(Suppl 3), pp.163~170 (1989)
  2. Meade EA, "Differential inhibition of prostaglandin endoperoxide synthase(cyclooxygenase)isozymes by aspirin and other non-steroidal anti-inflammatory drugs", J Biol Chem, 268, pp.6610~6614 (1993)
  3. Warner TD, "Cyclooxygenases : new forms, new inhibitors, and lessons from the clinic", FASEB J, 18, pp.790~804 (2004)
  4. Bresalier RS, "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial", N Engl J Med, 352, pp.1092~1102 (2005)
  5. Nussmeier NA, "Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery", N Engl J Med, 352, pp.1081~1091 (2005)
  6. Simon LS, "Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis : a randomized controlled trial", JAMA, 282, pp.1921~1928 (1999)
  7. Emery P, "Celecoxib versus diclofenac in long-term management of rheumatoid arthritis : randomised double-blind comparison", Lancet, 354, pp.2106~2111 (1999)
  8. Silverstein FE, "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis : the CLASS study : a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study", JAMA, 284, pp.1247~1255 (2000)
  9. Bensen WG, "Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor : a randomized controlled trial", Mayo Clin Proc, 74, pp.1095~1105 (1999)
  10. Dougados M, "Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis : a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug", Arthritis Rheum, 44, pp.180~185 (2001)
  11. Wiesenhutter CW, "Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis : a randomized, double-blind, placebo-controlled trial", Mayo Clin Proc, 80, pp.470~479 (2005)
  12. Yoo MC, "Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial", Curr Med Res Opin, 30, pp.2399~2408 (2014)
  13. 성윤경, "한국인 류마티스 관절염 환자에 대한에토리콕시브 90 mg의 안전성 및 유효성", 대한류마티스학회지, 12(4), pp.291~303 (2005), 대한류마티스학회
  14. Baraf HS, "Gastrointestinal side effects of etoricoxib in patients with osteoarthritis : results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness(EDGE)trial", J Rheumatol, 34, pp.408~420 (2007)
  15. Hunt RH, "The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events", Am J Gastroenterol, 98, pp.1725~1733 (2003)
  16. Bhala N, "Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs : meta-analyses of individual participant data from randomised trials", Lancet, 382, pp.769~779 (2013)
  17. Leese PT, "Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults : a randomized, controlled trial", J Clin Pharmacol, 40, pp.124~132 (2000)
  18. Knijff-Dutmer EA, "The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users", QJM, 96, pp.513~520 (2003)
  19. Giovannucci E, "Aspirin and the risk of colorectal cancer in women", N Engl J Med, 333, pp.609~614 (1995)
  20. Asano TK, "Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer : a systematic review", Dis Colon Rectum, 47, pp.665~673 (2004)
  21. Eberhart CE, "Up-regulation of cyclooxygenase 2gene expression in human colorectal adenomas and adenocarcinomas", Gastroenterology, 107, pp.1183~1188 (1994)
  22. Sheng H, "Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2", J Clin Invest, 99, pp.2254~2259 (1997)
  23. DuBois RN, "Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors", Gastroenterology, 110, pp.1259~1262 (1996)
  24. Cianchi F, "Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer", Gastroenterology, 121, pp.1339~1347 (2001)
  25. Tsujii M, "Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential", Proc Natl Acad Sci U S A, 94, pp.3336~3340 (1997)
  26. Steinbach G, "The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis", N Engl J Med, 342, pp.1946~1952 (2000)
  27. Steven E. Nissen, "Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis", New England Journal of Medicine (2016), New England Journal of Medicine (NEJM[DOI]
  28. Cannon CP, "Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term(MEDAL)programme : a randomised comparison", Lancet, 368, pp.1771~1781 (2006)
  29. Trelle S, "Cardiovascular safety of non-steroidal anti-inflammatory drugs : network meta-analysis", BMJ, 342, pp.7086~ (2011)
  30. Perazella MA, "Selective cyclooxygenase-2 inhibitors : a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs", Am J Med, 111, pp.64~67 (2001)
  31. La Grenade L, "Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors", Drug Saf, 28, pp.917~924 (2005)
  32. Schellenberg RR, "Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor", N Engl J Med, 345, pp.1856~ (2001)
  33. Bonnel RA, "Aseptic meningitis associated with rofecoxib", Arch Intern Med, 162, pp.713~715 (2002)

관련 논문AI추천

비스테로이드 항염제이충기영남대학교 의과대학 · Journal of Yeungnam Medical Science2000 · 제17권 제1호비스테로이드성 항염증 약물의 임상적 이용김경수대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2004 · 제47권 제2호비스테로이드소염제로 인한 궤양 합병증 예방을 위한 비스테로이드소염제 사용 현황 및 적절성 평가신완균, 이은숙, 조정원한국임상약학회 · 한국임상약학회지2012 · 제22권 제3호호흡기상피세포에서 항염증제가 Interleukin-1β에 의한 Cyclooxygenase-2의 발현에 미치는 영향김용대, 박강식, 배창훈, 서영중, 송시연, 신재흔, 우현재대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2004 · 제47권 제10호혈관 반응성에 대한 Cyclooxygenase 억제제 효과와 Cyclooxygenase 발현 변화강영진, 박진우, 엄은아, 이광윤, 이기영, 최형철영남대학교 의과대학 · Journal of Yeungnam Medical Science2006 · 제23권 제1호노인환자에서 위장관계 및 심혈관계 부작용 발생 예방을 위한 NSAIDs 사용의 적절성 평가방준석, 주성락한국임상약학회 · 한국임상약학회지2014 · 제24권 제1호

이 간행물의 다른 논문 (11건)

입원환자전담의(Hospitalist) 제도의 준비 작업과 전망이동기pp. 241-244위식도역류 질환의 식도 외 증상박성철, 남승주, 이성준pp. 257-263손목굴증후군오지영, 김해림pp. 267-272심장 동종이식편 혈관병증에 대한 심장 재이식 1예전은석, 이수연, 최진오, 김유진, 최재신, 이가연, 김정선pp. 287-291재발성 연골염에 동반된 빠르게 크기가 증가하는 상행대동맥류 1예김동욱, 성기익, 김덕경, 김주원, 이대근, 장하성pp. 292-295
원문 보기